Stroke, Acute

Neurology
2
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
1
EGb761Phase 31 trial
Active Trials
NCT00276380Completed204Est. Mar 2009
Celularity
CelularityFLORHAM PARK, NJ
1 program
1
Human Placenta-Derived Cells PDA001-Phase 21 trial
Active Trials
NCT01310114Terminated44Est. Mar 2013
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
External Focus of AttentionN/A1 trial
Active Trials
NCT05874661Unknown16Est. Aug 2024
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
Magnetically Enhanced DiffusionN/A1 trial
Active Trials
NCT03098732SuspendedEst. Dec 2020
Rhythm Pharmaceuticals
1 program
Reveal LINQ™ Insertable Cardiac MonitorN/A1 trial
Active Trials
NCT02700945Completed496Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenEGb761
CelularityHuman Placenta-Derived Cells PDA001-
Mission TherapeuticsExternal Focus of Attention
Pulse BiosciencesMagnetically Enhanced Diffusion
Rhythm PharmaceuticalsReveal LINQ™ Insertable Cardiac Monitor

Clinical Trials (5)

Total enrollment: 760 patients across 5 trials

NCT00276380IpsenEGb761

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

Start: Feb 2003Est. completion: Mar 2009204 patients
Phase 3Completed
NCT01310114CelularityHuman Placenta-Derived Cells PDA001-

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

Start: Mar 2011Est. completion: Mar 201344 patients
Phase 2Terminated
NCT05874661Mission TherapeuticsExternal Focus of Attention

FOA on Sit to Stand in Individuals Post Stroke

Start: Apr 2023Est. completion: Aug 202416 patients
N/AUnknown
NCT03098732Pulse BiosciencesMagnetically Enhanced Diffusion

Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial

Start: Mar 2017Est. completion: Dec 2020
N/ASuspended
NCT02700945Rhythm PharmaceuticalsReveal LINQ™ Insertable Cardiac Monitor

Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Start: Mar 2016Est. completion: Jul 2022496 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)